Neil Martinson to Tuberculosis, Multidrug-Resistant
This is a "connection" page, showing publications Neil Martinson has written about Tuberculosis, Multidrug-Resistant.
Connection Strength
1,970
-
Occult rifampicin-resistant tuberculosis: better assays are needed. Lancet Infect Dis. 2018 12; 18(12):1293-1295.
Score: 0,518
-
Drug-resistant tuberculosis: the rise of the monos. Lancet Infect Dis. 2018 07; 18(7):705-706.
Score: 0,500
-
Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024 May 02; 68(5):e0158323.
Score: 0,189
-
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). Am J Respir Crit Care Med. 2022 May 15; 205(10):1214-1227.
Score: 0,166
-
Challenges in recruiting children to a multidrug-resistant TB prevention trial. Int J Tuberc Lung Dis. 2021 10 01; 25(10):814-822.
Score: 0,159
-
Evolving therapies for rifampicin-resistant tuberculosis: balancing efficacy and toxicity. Lancet Respir Med. 2020 04; 8(4):326-328.
Score: 0,143
-
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018 Dec 20; 19(1):693.
Score: 0,131
-
Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa. Trop Med Int Health. 2013 Jan; 18(1):109-16.
Score: 0,086
-
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011 Jul 07; 365(1):11-20.
Score: 0,078